{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:20:51Z","timestamp":1760833251734,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.nmd.2023.08.009","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:30:55Z","timestamp":1692757855000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A highly sensitive and quantitative assay for dystrophin protein using Single Molecule Count Technology"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-0445","authenticated-orcid":false,"given":"Misawa Niki","family":"Ishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Quinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kamiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2023.08.009_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Aartsma-Rus A. Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"10.1016\/j.nmd.2023.08.009_bib0002","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1074\/jbc.R200031200","article-title":"Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function","volume":"278","author":"Michele","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.nmd.2023.08.009_bib0003","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","article-title":"Membrane organization of the dystrophin-glycoprotein complex","volume":"66","author":"Ervasti","year":"1991","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.nmd.2023.08.009_bib0004","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.nmd.2023.08.009_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"issue":"2","key":"10.1016\/j.nmd.2023.08.009_bib0006","first-page":"117","article-title":"Survival in Duchenne muscular dystrophy","volume":"31","author":"Rall","year":"2012","journal-title":"Acta Myol"},{"year":"2022","series-title":"Becker muscular dystrophy","author":"Thada","key":"10.1016\/j.nmd.2023.08.009_bib0007"},{"issue":"10","key":"10.1016\/j.nmd.2023.08.009_bib0008","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.nmd.2023.08.009_bib0009","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.nmd.2023.08.009_bib0010","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"24","key":"10.1016\/j.nmd.2023.08.009_bib0011","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.nmd.2023.08.009_bib0012","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why dystrophin quantification is key in the Eteplirsen saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2023.08.009_bib0013","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JND-180357","article-title":"Report of a TREAT-NMD\/world Duchenne organisation meeting on dystrophin quantification methodology","volume":"6","author":"Aartsma-Rus","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.nmd.2023.08.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195850","article-title":"Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy","volume":"13","author":"Beekman","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2023.08.009_bib0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymeth.2018.10.018","article-title":"Quantitation of low abundant soluble biomarkers using high sensitivity Single Molecule Counting technology","volume":"158","author":"Hwang","year":"2019","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.nmd.2023.08.009_bib0016","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.nmd.2023.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10\u201311","key":"10.1016\/j.nmd.2023.08.009_bib0018","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41434-021-00300-7","article-title":"Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy","volume":"29","author":"Farrokhi","year":"2022","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.nmd.2023.08.009_bib0019","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"issue":"5","key":"10.1016\/j.nmd.2023.08.009_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0969-2126(00)00132-5","article-title":"The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy","volume":"8","author":"Norwood","year":"2000","journal-title":"Structure"},{"issue":"2","key":"10.1016\/j.nmd.2023.08.009_bib0021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","article-title":"Dystrophin complex functions as a scaffold for signalling proteins","volume":"1838","author":"Constantin","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"437","key":"10.1016\/j.nmd.2023.08.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.nmd.2023.08.009_bib0023","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ana.25951","article-title":"Very low residual dystrophin quantity is associated with milder dystrophinopathy","volume":"89","author":"de Feraudy","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2023.08.009_bib0024","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acn3.319","article-title":"Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy","volume":"3","author":"Godi","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.08.009_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nmd.2010.03.007","article-title":"Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials","volume":"20","author":"Arechavala-Gomeza","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.nmd.2023.08.009_bib0026","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","article-title":"Dystrophin levels and clinical severity in Becker muscular dystrophy patients","volume":"85","author":"van den Bergen","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.nmd.2023.08.009_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040241","article-title":"Genotype-phenotype correlations in duchenne and becker muscular dystrophy patients from the Canadian neuromuscular disease registry","volume":"10","author":"Lim","year":"2020","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.nmd.2023.08.009_bib0028","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","article-title":"Becker muscular dystrophy severity is linked to the structure of dystrophin","volume":"24","author":"Nicolas","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.nmd.2023.08.009_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030111","article-title":"Advances in genetic characterization and genotype-phenotype correlation of duchenne and becker muscular dystrophy in the personalized medicine era","volume":"10","author":"Sheikh","year":"2020","journal-title":"J Pers Med"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623006934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623006934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:59Z","timestamp":1760775239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623006934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0960896623006934"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.08.009","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A highly sensitive and quantitative assay for dystrophin protein using Single Molecule Count Technology","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}